Kiora Pharmaceuticals (KPRX) Shares Outstanding (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Shares Outstanding (Entity) came in at $4.0 million in Q1 2026, down 5.3% YoY from $4.2 million in Q1 2025, and up 6.16% on a QoQ basis from $3.8 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Shares Outstanding (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Shares Outstanding (Entity) data on file, last reported at $4.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) fell 5.3% year-over-year to $4.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.0 million (down 5.3% YoY) and the FY2025 annual result came in at $3.8 million, down 2.86% from the prior year.
- Shares Outstanding (Entity) rose to $4.0 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $4.2 million in Q1 2025 to a low of $35177.0 in Q1 2022.
- A 5-year average of $2.1 million and a median of $2.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 1268.03% — and 2025, when it retreated 18.54%.
- Tracing KPRX's Shares Outstanding (Entity) over 5 years: stood at $81366.0 in 2022, then surged by 561.21% to $538002.0 in 2023, then surged by 619.82% to $3.9 million in 2024, then decreased by 2.86% to $3.8 million in 2025, then gained by 6.16% to $4.0 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $4.0 million (Q1 2026), $3.8 million (Q4 2025), and $3.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | 6.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.18 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Dec 31, 2025 | 4.17 Mn |
| Sep 30, 2025 | 4.29 Mn |
| Jun 30, 2025 | 3.99 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | 3.87 Mn |
| Sep 30, 2024 | 4.21 Mn |
| Jun 30, 2024 | 4.17 Mn |
| Mar 31, 2024 | 2.88 Mn |
| Dec 31, 2023 | 538,002.00 |
| Sep 30, 2023 | 789,648.00 |
| Jun 30, 2023 | 365,527.00 |
| Mar 31, 2023 | 207,050.00 |
| Dec 31, 2022 | 81,366.00 |
| Sep 30, 2022 | 94,281.00 |
| Jun 30, 2022 | 36,293.00 |
| Mar 31, 2022 | 36,274.00 |
| Dec 31, 2021 | 25,668.00 |
| Sep 30, 2021 | 28,514.00 |